Loading
institutionsInstitution
The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute
Where John Byrd's team turned ibrutinib into the drug that transformed chronic lymphocytic leukaemia; Ohio State's NCI comprehensive centre.
Also called: OSUCCC-JamesThe James
Overview
NCI-designated since 1976, the OSUCCC-James is one of the few free-standing cancer hospitals in the US and Ohio's largest cancer research enterprise. John Byrd and colleagues ran the defining early and phase 3 trials of ibrutinib (RESONATE) and acalabrutinib in CLL, and Clara Bloomfield's cytogenetic and molecular classification of acute myeloid leukaemia underpins today's ELN risk groups. Carlo Croce discovered the role of microRNAs in cancer and mapped BCL2 to the t(14;18) translocation in follicular lymphoma. Former director Michael Caligiuri built its NK cell and immunology programme, and Raphael Pollock leads a national sarcoma programme. Pelotonia, an annual cycling event, funds much of the centre's research.
Location
Columbus, OH, US
Type
cancer center · The Ohio State University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#68 · 45 points (0 Newsweek + 15 NCI + 30 from 15 linked objects) · ranking
- CLL and BTK inhibitors
- AML classification
- MicroRNA biology
- Sarcoma
Jennifer A. Woyach
Professor of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center
Chronic lymphocytic leukaemiaBTK inhibitorsOlder patients
Led Alliance A041202, which showed ibrutinib beats chemoimmunotherapy in older CLL patients, and discovered BTK C481S resistance.
Michael A. Caligiuri
President, City of Hope National Medical Center; Deana and Steve Campbell Physician-in-Chief; AACR Treasurer
Natural killer cellsLeukaemiaImmunotherapy
Michael Caligiuri is an NK cell immunologist and past AACR president who leads City of Hope's hospital.
Similar pages
- TrialBELLWAVE-011
Shares Acalabrutinib, BTK (Bruton tyrosine kinase), Ibrutinib, Chronic lymphocytic leukaemia.
- PersonJohn C. Byrd
Shares RESONATE, Beat AML Master Trial, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors.
- Key paperAMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients
Shares Jennifer A. Woyach, Acalabrutinib, BTK (Bruton tyrosine kinase), BCL-2.
- TrialGLOW
Shares BTK (Bruton tyrosine kinase), Ibrutinib, BCL-2, Chronic lymphocytic leukaemia.
- TrialStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Shares Acalabrutinib, Ibrutinib, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors.
- TrialAMPLIFY
Shares Acalabrutinib, BTK (Bruton tyrosine kinase), BCL-2, Chronic lymphocytic leukaemia.
- PairingBTK inhibitor + venetoclax, fixed duration
Shares Acalabrutinib, BTK (Bruton tyrosine kinase), Ibrutinib, BCL-2.
- TrialCAPTIVATE
Shares BTK (Bruton tyrosine kinase), Ibrutinib, BCL-2, Chronic lymphocytic leukaemia.
cancers
technologies
targets
drugs
ApprovedSmall-molecule covalent BTK inhibitor (second generation)
Acalabrutinib · Calquence
ApprovedSmall-molecule covalent BTK inhibitor (first generation)
Ibrutinib · Imbruvica